within Pharmacolibrary.Drugs.C_CardiovascularSystem.C01E_OtherCardiacPreparations.C01EA01_Alprostadil;

model Alprostadil
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 3.266666666666666e-05,
    adminDuration = 600,
    adminMass = 20 / 1000000,
    adminCount = 1,
    Vd = 0.0004,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0001,
    k12 = 4.6666666666666665e-05,
    k21 = 4.6666666666666665e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Alprostadil</td></tr><tr><td>ATC code:</td><td>C01EA01</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>20</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.4</td><td>L</td></tr>
    <tr><td>clearance:</td><td>28</td><td>mL/min/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Alprostadil is a synthetic prostaglandin E1 (PGE1) used primarily for the treatment of erectile dysfunction and to maintain ductus arteriosus patency in newborns with specific congenital heart defects. It is approved and used today, typically administered via intracavernosal injection, intraurethral placement, or intravenous infusion in neonates.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in healthy adult males following intravenous administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.C.C01EA01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Alprostadil;
